Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Biogen Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on GE Healthcare Technologies Inc (GEHC), Biogen (BIIB)...

Analysts Offer Insights on Healthcare Companies: GE Healthcare Technologies Inc (GEHC), Biogen (BIIB) and BeOne Medicines (ONC)

Biogen Inc. ($BIIB) announced an update on their ongoing clinical study. Biogen Inc. has launched a Phase 2 trial testing felzartamab in adults wit...

Biogen Expands Autoimmune Pipeline With New Graves’ Disease Trial

Insiders have been trading these 5 stocks: (($GD)), (($TMO)), (($CVNA)), (($BIIB)) and (($SCHW)). Here is a breakdown of their recent trades and th...

Insiders Shake Up General Dynamics, Thermo Fisher, Carvana, Biogen, Charles Schwab

Biogen Inc. ($BIIB) announced an update on their ongoing clinical study. Biogen extends study of kidney rejection drug felzartamab This long-term e...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BIIB	$220.83	-1.64%	464.80K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BIIB	$220.83	-1.6%	464.80K
3
4
5
6

BIIB

Get Biogen Inc. Data in Excel

Get Biogen Inc. Data in Excel